Overexpression of tumour necrosis factor-α-converting enzyme in psoriasis

被引:48
作者
Kawaguchi, M [1 ]
Mitsuhashi, Y [1 ]
Kondo, S [1 ]
机构
[1] Yamagata Univ, Sch Med, Dept Dermatol, Yamagata 9909585, Japan
关键词
immunohistochemistry; psoriasis; real-time quantitative reverse transcription-polymerase chain reaction; tumour necrosis factor-alpha; tumour necrosis factor-alpha-converting enzyme;
D O I
10.1111/j.1365-2133.2005.06440.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Tumour necrosis factor (TNF)-α-converting enzyme (TACE) is a metalloproteinase-disintegrin that releases soluble TNF-α from cells by cleaving within the extracellular domain of membrane-bound pro-TNF-α. It was proposed that TNF-α is involved in the pathogenesis of psoriasis, and it is therefore suggested that TACE has important roles in psoriasis. However, it is unclear whether TACE is expressed in psoriatic tissue. Objectives To clarify whether TACE is expressed in psoriatic lesions and whether expression levels of TACE mRNA are increased in lesional compared with nonlesional psoriatic skin. Methods Skin biopsies were obtained from patients with psoriasis. We examined the expression of TACE in psoriatic tissues using a novel real-time quantitative reverse transcriptase-polymerase chain reaction method and immunohistochemical analysis. Results There was a significant rise in the level of TACE mRNA expression in lesional psoriatic skin compared with nonlesional skin in all patients. There was a statistically significant rise in the level of TACE mRNA expression in lesional psoriatic skin compared with nonlesional skin (mean ± SD TACE/glyceraldehyde-3-phosphate dehydrogenase ratio 0.031 ± 0.012 vs. 0.009 ± 0.002, P < 0.05). In lesional psoriatic skin, immunostaining with anti-TACE antibody was present throughout all layers of the epidermis. TACE immunostaining was found in the cytoplasm of keratinocytes. There was staining associated with blood vessels in the papillary dermis and perivascular inflammatory cells. In particular, mast cells showed strong staining. They contained numerous granules that were stained for TACE in the cytoplasm. Conclusions The findings of the present study suggest that elevation of TACE mRNA in psoriatic lesions is due to many cells, particularly mast cells, that function in lesional psoriatic skin as an important source of TNF-α and other cytokines.
引用
收藏
页码:915 / 919
页数:5
相关论文
共 31 条
[1]   Tumour necrosis factor blocking agents: a new therapeutic modality for inflammatory disorders [J].
Abuzakouk, M ;
Feighery, C ;
Jackson, J .
BRITISH JOURNAL OF BIOMEDICAL SCIENCE, 2002, 59 (03) :173-179
[2]   Mast cells of psoriatic and atopic dermatitis skin are positive for TNF-α and their degranulation is associated with expression of ICAM-1 in the epidermis [J].
Ackermann, L ;
Harvima, IT .
ARCHIVES OF DERMATOLOGICAL RESEARCH, 1998, 290 (07) :353-359
[3]   Mechanisms of disease - Nuclear factor-kappa b - A pivotal transcription factor in chronic inflammatory diseases [J].
Barnes, PJ ;
Larin, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (15) :1066-1071
[4]   A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells [J].
Black, RA ;
Rauch, CT ;
Kozlosky, CJ ;
Peschon, JJ ;
Slack, JL ;
Wolfson, MF ;
Castner, BJ ;
Stocking, KL ;
Reddy, P ;
Srinivasan, S ;
Nelson, N ;
Boiani, N ;
Schooley, KA ;
Gerhart, M ;
Davis, R ;
Fitzner, JN ;
Johnson, RS ;
Paxton, RJ ;
March, CJ ;
Cerretti, DP .
NATURE, 1997, 385 (6618) :729-733
[5]   The pathogenesis of psoriasis: Immunological facts and speculations [J].
Bos, JD ;
De Rie, MA .
IMMUNOLOGY TODAY, 1999, 20 (01) :40-46
[6]  
BRADDING P, 1995, J IMMUNOL, V155, P297
[7]   INTERLEUKIN-4, INTERLEUKIN-5, AND INTERLEUKIN-6 AND TUMOR-NECROSIS-FACTOR-ALPHA IN NORMAL AND ASTHMATIC AIRWAYS - EVIDENCE FOR THE HUMAN MAST-CELL AS A SOURCE OF THESE CYTOKINES [J].
BRADDING, P ;
ROBERTS, JA ;
BRITTEN, KM ;
MONTEFORT, S ;
DJUKANOVIC, R ;
MUELLER, R ;
HEUSSER, CH ;
HOWARTH, PH ;
HOLGATE, ST .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1994, 10 (05) :471-480
[8]   Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial [J].
Chaudhari, U ;
Romano, P ;
Mulcahy, LD ;
Dooley, LT ;
Baker, DG ;
Gottlieb, AB .
LANCET, 2001, 357 (9271) :1842-1847
[9]  
Conway JG, 2001, J PHARMACOL EXP THER, V298, P900
[10]  
Dethlefsen SM, 1998, J CELL BIOCHEM, V69, P143, DOI 10.1002/(SICI)1097-4644(19980501)69:2<143::AID-JCB5>3.0.CO